Algorae Pharmaceuticals Limited has released a press release.
LCT Strategy Update
Filed with ASX ·
On 6ix: 6ix.com/news/lct-strategy-update
6ix hasn’t read this filing yet.
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- LCT to sell JV Shares and receive DIABECELL licence
- Appendix 4C - Quarterly
- Results of LCT Parkinsons trial require further analysis
- LCT files pericyte protective agent provisional patent
- Appendix 4C Quarterly Cash Flow Report 30 September 2017
Later from Algorae Pharmaceuticals
- NTCELL and Parkinsons trial update
- Preliminary Final Report and 2018 Financial Statements
- NTCELL Parkinsons trial patient data at 18 months
- NTCELL Parkinsons trial patient data 2 years after implant
- Preliminary Final Report and 2019 Financial Statements
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals